TERT promoter mutations in skin cancer: The effects of sun exposure and X-irradiation

Journal of Investigative Dermatology

Volumn 134, Issue 8, 2014, Pages 2251-2257

  Pópulo, Helena ^a   Boaventura, Paula ^a   Vinagre, João ^a   Batista, Rui ^a   Mendes, Adélia ^a   Caldas, Regina ^b   Pardal, Joana ^c   Azevedo, Filomena ^c   Honavar, Mrinalini ^d   Guimarães, Isabel ^d   Manuel Lopes, José ^a,b,c   Sobrinho Simões, Manuel ^a,b,c   Soares, Paula ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d HOSPITAL PEDRO HISPANO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; MUTATION RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUN EXPOSURE; ULTRAVIOLET RADIATION; X IRRADIATION;

CARCINOMA, BASAL CELL; HUMANS; MELANOMA; MUTATION; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; SUNLIGHT; TELOMERASE; X-RAYS;

EID: 84904458479     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.163     Document Type: Article

References (26)

1. Allory Y, Beukers W, Sagrera A et al. (2013) Telomerase reverse transcriptase promoter mutations in bladder cancer: High frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65:360-6
2. Balch CM, Gershenwald JE, Soong SJ et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-206
3. Boaventura P, Oliveira R, Pereira D et al. (2012) Head and neck basal cell carcinoma prevalence in individuals submitted to childhood X-ray epilation for tinea capitis treatment. Eur J Dermatol 22:225-30
4. Boaventura P, Soares P, Pereira D et al. (2011) Head and neck lesions in a cohort irradiated in childhood for tinea capitis treatment. Lancet Infect Dis 11:163-4
5. Chiu CP, Harley CB (1997) Replicative senescence and cell immortality: The role of telomeres and telomerase. Proc Soc Exp Biol Med 214: 99-106
6. Chudnovsky Y, Khavari PA, Adams AE (2005) Melanoma genetics and the development of rational therapeutics. J Clin Invest 115:813-24
7. Dessinioti C, Tzannis K, Sypsa V et al. (2011) Epidemiologic risk factors of basal cell carcinoma development and age at onset in a Southern European population from Greece. Exp Dermatol 20:622-6
8. Griewank KG, Murali R, Schilling B et al. (2013) TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 8:e80354
9. Hassanpour SE, Kalantar-Hormozi A, Motamed S et al. (2006) Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: A retrospective study and comparison to nonirradiated patients. Ann Plast Surg 57:509-12
10. Horn S, Figl A, Rachakonda PS et al. (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959-61
11. Huang FW, Hodis E, Xu MJ et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-9
12. Killela PJ, Reitman ZJ, Jiao Y et al. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021-6
13. Melo M, Rocha AG, Vinagre J et al. (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (jc20133734) e-pub ahead of print 29 January 2014
14. O'Driscoll L, McMorrow J, Doolan P et al. (2006) Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Mol Cancer 5:74
15. Populo H, Soares P, Lopes JM (2012) Insights into melanoma: Targeting the mTOR pathway for therapeutics. Expert Opin Ther Targets 16: 689-705
16. Populo H, Soares P, Rocha AS et al. (2010) Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 20:107-17
17. Preto A, Cameselle-Teijeiro J, Moldes-Boullosa J et al. (2004) Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests. Mod Pathol 17:819-26
18. Rachakonda PS, Hosen I, de Verdier PJ et al. (2013) TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA 110:17426-31
19. Rady P, Scinicariello F, Wagner RF Jr. et al. (1992) p53 mutations in basal cell carcinomas. Cancer Res 52:3804-6
20. Reifenberger J, Wolter M, Knobbe CB et al. (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152:43-51
21. Remke M, Ramaswamy V, Peacock J et al. (2013) TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 126:917-29
22. Scott GA, Laughlin TS, Rothberg PG (2013) Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol 27:516-23
23. Shay JW, Wright WE (1996) The reactivation of telomerase activity in cancer progression. Trends Genet 12:129-31
24. Tessone A, Amariglio N,Weissman O et al. (2012) Radiotherapy-induced basal cell carcinomas of the scalp: Are they genetically different Aesthetic Plast Surg 36:1387-92
25. Tolleson WH (2005) Human melanocyte biology, toxicology, and pathology. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 23:105-61
26. Vinagre J, Almeida A, Populo H et al. (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185